NEW YORK, January 1, 2026, 16:48 ET — Market closed
- Intuitive Surgical ended the last 2025 session lower as U.S. markets headed into the New Year’s Day holiday.
- Investors are now focused on January catalysts, led by the company’s next quarterly update.
Shares of Intuitive Surgical, Inc. (ISRG) fell 1.1% to close at $566.36 on Wednesday, the final trading session of 2025, before U.S. stock markets closed for New Year’s Day.
The year-end dip matters now because the first trading days of January often bring portfolio rebalancing, and high-multiple healthcare names can be sensitive to shifts in risk appetite. For Intuitive, the next key test is whether its upcoming results and outlook keep investors confident in procedure-driven demand for robotic surgery.
Wall Street ended 2025’s final session lower, with the S&P 500 down 0.74% and the Nasdaq Composite off 0.76% in thin, holiday-shortened trading, Reuters reported. “I do not expect the last few days will have much bearing on next year,” said Giuseppe Sette, Reflexivity co-founder and president. Reuters
ISRG traded between $565.77 and $573.28 on Wednesday, with about 992,500 shares changing hands.
The stock’s 52-week range runs from roughly $425 to $616, leaving it about 8% below the top of that band.
Medtech peers also slipped, with Medtronic down about 0.6% and Stryker off about 0.8% in the same session.
Intuitive makes the da Vinci robotic surgery platform used in minimally invasive procedures. Investors tend to track procedure volume closely because it drives recurring demand for instruments and service tied to the installed base.
For traders, the lack of price action on Thursday keeps attention on whether year-end profit-taking extends into the first full session of 2026 when markets reopen on Friday. Early January flows can move large-cap healthcare names even without company-specific news.
Rates remain a key swing factor for equity valuations. The Federal Reserve’s next policy meeting is scheduled for Jan. 27-28, Reuters reported.
Intuitive has listed a fourth-quarter earnings conference call for Jan. 22, according to the company’s investor calendar. Investors will be watching for commentary on procedure trends, system placements and margins.
Technically, traders will watch whether the stock holds above Wednesday’s $565.77 low and whether it can regain the upper-$570s area, while the $616 level marks the top end of its 52-week range.
Any fresh updates on hospital capital spending, reimbursement signals or competitive moves in surgical robotics could shift the near-term narrative, but the next hard company catalyst is the January earnings report.
